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BULLETED STATEMENTS 
What is already known on this topic? 
Epidermolysis bullosa simplex generalized severe (EBS-gen sev) is a rare disabling skin 
disorder related to skin fragility. 
What this article adds to our knowledge? 
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We showed the presence of an immune infiltrate characterized by a Th17 phenotype in the 
skin of EBS-gen sev patients, and a marked improvement of skin condition in EBS patients 
after treatment with Apremilast, an anti-Th17 molecule.  
 
SUMMARY 
Background: Epidermolysis bullosa simplex generalized severe is a genetic disorder caused 
by mutation in KRT5 or KRT14 genes. Usually considered as a mechanical disease, recent 
data argue for additional inflammatory mechanisms.  
Objectives: The aim of this study was to assess the inflammation in the skin of patients with 
EBS. 
Methods: A first immunohistochemical retrospective study was performed on frozen skin 
samples from 17 EBS-gen sev patients. A second multicenter prospective study was 
conducted on 10 patients with severe EBS-gen sev. Blister fluid and epidermis were 
processed for immunochemistry analysis and quantitative real time PCR. Cytokine expression 
was analyzed in blister fluid and compared with controls. 
Results: Histological analysis showed a constant dermal perivascular CD4+ lymphocytes 
infiltrate in skin biopsies of blister (n=17) as well as in rubbed skin (n=5), an epidermal 
infiltration of neutrophils and eosinophils in 70% of cases and an increased immunostaining 
for CXCL9 and CXCL10 in blistering skin. High levels of Th17 cytokines were detected in 
lesional skin. Three adult patients with EBS-gen sev were treated with apremilast with a 
dramatic improvement of skin blistering and good tolerance.  
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Conclusion: Our study demonstrates the importance of inflammation in EBS-gen sev patients 
and underlines the key role for Th17 cells in its pathogenesis. In addition, this study provides 
promising new therapeutic approaches for this disabling disorder. 
 
INTRODUCTION 
Epidermolysis bullosa is a group of hereditary disorders characterized by skin and mucosal 
fragility resulting in post-traumatic blistering
1
. In EB simplex generalized severe (EBS-gen 
sev), blisters are present at birth, have a herpetiform pattern
2
 and involve mucosa. Progressive 
improvement with age is common, but there is an increased neonatal mortality due to 
development of severe infections
3
. The disease results from mutations affecting either keratin 
14 (K14) or 5 (K5), type I and type II intermediate filament (IF) proteins, respectively, 
expressed in basal keratinocytes in the epidermis
4
. EBS-gen sev was initially considered to be 
a mechanical disease due to the fragility of the patients’ keratinocytes5. However, this theory 
fails to explain all the clinical features of the disease and recent studies have suggested that 
additional inflammatory mechanisms may be involved
6-11
. The later hypothesis is supported 
by growing evidence for distinct regulatory functions of keratins in skin immunity and 
inflammation
12-15
, and encouraging results of topical anti-inflammatory treatments
16
. We have 
shown, for the first time, the presence of an immune infiltrate characterized by a Th17 
phenotype in the skin of EB gen-sev patients, and a marked improvement of skin condition in 
EBS-gen sev patients after the use of Apremilast, an anti-Th17 molecule, suggesting a 
promising new treatment of this disabling disorder.  
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MATERIAL AND METHODS 
The aim of this study was to analyze the skin inflammation associated with EBS-gen sev. Our 
study consisted of 2 parts: first, an immune-histochemical retrospective study using frozen 
skin samples and secondly, a multi-center prospective study. Molecular analysis was 
performed by the Scottish Molecular Genetic Consortium of Dundee University as previously 
described
17
.   
Patients  
Retrospective study: All patients with EBS-gen sev, who had skin biopsies at the edge of a 
non-infected blister taken between 1996 and 2012 for diagnosis and whose tissue was stored 
at -80°C were enrolled following their written consent. Diagnosis of EBS-gen sev was 
established on the association of clinical and immune-histological criteria.  
Prospective study design: Patients older than 1 year of age from both sexes, who were 
diagnosed with EBS-gen sev, and who developed more than 2 new blisters per day, were 
eligible for this study. Six French centers participated during the period (March-October 
2012). All procedures were approved by the Human Ethics Committees. Informed consent 
was obtained from all patients. In each center, following dermatological examination of the 
patient, the investigators filled in a standardized questionnaire and obtained the following 
biological samples: a) liquid content of at least 3 blisters (pooled in the same dry tube), and b) 
2 blister roofs (one fixed in formalin for immunohistochemistry and one in RNAlater for 
RNA extraction).  
Controls: Samples were obtained from 4 healthy volunteers, in whom blisters were induced 
by mechanical suction of the skin.  
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Therapeutic pilot study: Following the promising results seen with the initial biological data 
obtained, we proposed to 3 EBS-gen sev adult patients with disabling generalized blistering to 
start treatment with Apremilast.  
Histological and Immuno-histochemical analysis 
For the retrospective study, most skin samples were frozen. For the prospective study, the 
roofs of blisters had been conserved in Tissue-Tek® and stored at -80°C. 
Skin sections were prepared and stained with hematoxylin-phloxine-saffron (HPS) (for 
assessing the cellular infiltrate), and immune-labeled for CD4 and CD8 T-cells or chemokine 
(C-X-C motif) ligands CXCL-9 and CXCL10. Detailed technique is available in 
supplementary data 1.  
Analysis of gene expression in the blister roofs / RNA extraction and RT-PCR: 
After fixation of blister roofs in RNAlater for 24 hours at 4°C, total RNA was extracted using 
the RNeasy extraction Kits (Qiagen) according to the manufacturer’s protocol. RNA quantity 
was measured using a Nanodrop Spectrophotometer ND8000 (Thermo Fisher Scientific, 
Waltham, MA, USA). cDNA was prepared by reverse transcription with oligo-dT using the 
Omniscript RT kit (Qiage) and used as a template for amplification by PCR with specific 
primers directed against Th1, Th2 and Th17 cytokine genes. mRNA was expressed as relative 
quantity above housekeeping gene control.  
Cytokine analysis in the blister fluid: 
The blister fluids were stored at 4°C and sent to the lab within 24 hours. Liquids were 
centrifuged at at 2000 rpm for 10 minutes at 4°C. The supernatants were collected and frozen 
at -80°C. Immunoassays based on Luminex™ xMAP™ (multi-analyze profiling) technology 
was done on the blister’s fluid for detection and quantitation of cytokines.  
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 RESULTS: 
EBS-gen sev patients have clinical hallmarks of inflammatory skin disease  
Seventeen patients with EBS-gen sev were included in the retrospective study and 10 in the 
prospective study. Five patients participated in both arms of the study. Clinical and biological 
features are summarized in Table 1.  
All patients had flare-ups of their disease and complained of spontaneous and unexplained 
flare-ups.  Interestingly, inflammatory or general factors such as cutaneous infection (7/10), 
vaccines (2/10), teeth eruption (4/10) and fever (3/10) were reported to induce blisters 
whereas improvement was induced by protecting the skin from friction and cold, application 
of topical steroids (4/10), fever (3/10) and use of local or systemic antibiotics (7/10). 
The blisters were often preceded by erythema, suggesting a pre-existing local inflammation 
(8/10) and in those cases, some patients reported that topical application of steroids could 
prevent the onset of blisters. 
The mean duration of wound healing ranged from a few days (4/10) to two weeks (3/10). The 
majority of patients reported the development of non-healing blisters (8/10) over friction 
areas, with chronic extensive blisters. Emollient creams or petrolatum cream (6/10) and also 
topical antibiotics (7/10) were reported to be effective by patients, even without clinical 
infection. 
Patients with EBS-gen sev have a perivascular dermal CD4+ lymphocytic infiltrate in 
blistering and rubbed skin. 
Twenty-two frozen skin biopsies were analysed in the retrospective study. Among the 17 
patients included, 5 had also a skin biopsy taken from rubbed, normal-looking skin. 
Examination of the HPS-stained sections showed a dermal inflammatory infiltrate in all 
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biopsies (Figure 1a). This infiltrate was always localized in the superficial dermis with a 
perivascular distribution; it was sparse (+) in 11 biopsies, moderate (++) in 9 biopsies and 
dense (+++) in 2 biopsies. Infiltrating cells were predominantly lymphocytic; neutrophils 
were detected in only 2 patients and eosinophils in 1 patient.  
Immuno-histochemical staining for T-cell antigens showed that the inflammatory infiltrate 
mainly consisted of CD3+ T lymphocytes (Fig. 1b). Analysis of the lymphocytic subsets CD4 
and CD8 T cells (Fig. 1c and 1d) showed that the infiltrate mainly composed of CD4+ 
lymphocytes (19/21 cases) (Fig. 1c). There was no difference in the type and the degree of 
immune infiltrate according to the mutational profile (KRT5 vs KRT14). Interestingly, 
analysis of biopsies taken from rubbed skin showed similar results (Supplementary Fig. 1).  
 
Infiltration with eosinophils and neutrophils can be present in lesional skin (Fig. 2) 
For 5 patients from the retrospective study, histological analysis of a non-frozen skin biopsy 
of a blister was possible. An eosinophilic infiltrate was present in 4 of these patients in the 
dermis (4) and/or the epidermis (2). These eosinophils were not visible on the frozen sections, 
suggesting the limitation of this technique.  
The prospective study included 10 roof blisters. Immunochemistry showed necrosis of the 
epidermis in all patients. Six patients had a dense epidermal neutrophilic infiltrate with 
eosinophils in 2 cases. In two patients the infiltrate was merely made of eosinophils. Two 
patients had no inflammatory cells in the epidermis.  
The blister roof and fluid of EBS-gen sev overexpress Th17 cytokines (Fig. 3- 4). 
Analysis of cytokine mRNA expression by Q-PCR in the blister roof was possible for 6 
patients and results were compared to 4 controls. The levels of interleukin (IL) 8, a neutrophil 
chemoattractant produced by keratinocytes and macrophages, were elevated in all patients 
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(6/6), as were markers of Th17 immune response, including IL-17 (6/6), IL-21 (6/6) and IL-
22 (4/6), which were significantly elevated compared with controls (Figure 3). The levels of 
Th1 [interferon gamma (IFN and tumor necrosis factor alpha (TNF] and Th2 cytokines 
(IL-4, IL-5) remained unchanged, however T-regulatory cytokines [IL-10 and transforming 
growth factor beta (TGFβ)] were elevated above baseline in 4/6 and 6/6 patients, respectively 
(Fig. 3). 
The cytokine protein content of the blister fluid was analyzed in 8 EBS-gen sev patients and 
was compared with the blister fluid from 4 healthy controls. We found significantly increased 
levels of TNFα and Chemokine (C-C motif) ligand 20 (CCL20), two inflammatory cytokines, 
IL-5 (a Th2 cytokine) and IL-22 (Fig. 4). Other Th2 cytokines, such as IL-4 and IL-13, 
remained unchanged. The levels of Th1 cytokines IFN IL-6 and IL-1β were increased but 
the difference failed to reach statistical significance (Supplementary Fig. 2).  
Finally, analysis of Th17 cytokines at the protein level supported the data obtained at the 
mRNA level, which showed increased levels of IL-17A, IL-17F, IL-21 and IL-22 (Fig. 4). 
Taken together, these results argue for the role of inflammation, and especially inflammation 
mediated by Th17 cells, in the pathogenesis of EBS-gen sev. 
 
Blistering skin of patients with EBS-gen sev overexpresses CXCL-9 and CXCL10  
Keratinocytes are potent attractants for immune cells as they secrete large amounts of 
chemokines
18-19
. We thus hypothesized that an increased production of chemokines in EBS-
gen sev skin could be the initiating event for the immune infiltrate. Using EBS-gen sev skin 
from 4 children with the disease and 4 skins from healthy controls, we have found 
significantly increased number of CXCL9 and CXCL10-immunopositive cells in EBS-gen 
sev skin compared with controls (Fig. 5). 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Treatment of EBS-gen sev patients with Apremilast improves cutaneous symptoms (Fig. 6). 
Based on these data, we initiated a treatment with Apremilast in 3 adult patients (3 women 
aged 33 to 55 years) with EBS-gen sev. Apremilast is a small molecule which specifically 
inhibits cyclic AMP phosphodiesterase-4 and Th1/Th17 activation and has been approved for 
the treatment of psoriasis
20, 21
. Patients 1 and 2 were a mother and her daughter with K5 
mutation, mutational status was unknown for patient 3. Before treatment, all patients had at 
least 4 or 5 body zones with chronic active blistering, despite protective measures and topical 
treatments. The patients started Apremilast according to the psoriasis regimen (progressive 
increase of daily dose from 10mg/d to 30mg twice daily
20
) in spring or summer. After 10, 15 
and 30 days respectively, a dramatic decrease in the number of blisters was observed. The 3 
patients initially complained of mild abdominal pain and diarrhea, which progressively 
disappeared within one month. Patient 3 complained of persistent nausea and stopped the 
treatment after 7 months. No other adverse events were reported. There was no recurrence 
after 10 and 8 months of treatment for patient 1 and 2 respectively. Patient 3 had recurrence of 
blistering two days after the discontinuation of Apremilast.  
 
DISCUSSION 
In our study we confirm that patients with EBS-gen sev have clinical hallmarks of an 
inflammatory skin disease. Furthermore, patients have a dermal infiltrate of CD3+CD4+ 
lymphocytes in lesional and, to a lesser extent, in non-lesional skin, and epidermal necrosis, 
suggesting a role for cell-mediated immunity. These results are in accordance with 
litterature
10, 11
. Keratinocytes are the main cells producing CXCL9, CXCL10 and CCL20, 
three potent attractors of lymphocytes in the skin of patients with several auto-immune skin 
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diseases or in the early phases of wound healing
18, 22-24
. Consistent with these results we found 
an increased expression of CXCL9 and CXCL10 in the lesional skin compared with control 
skin, and an increased level of CCL20 in the blister fluid of patients, suggesting that these 
chemokines are likely to play an important role in lymphocytic infiltrate. An upregulation of 
CCL2 and CCL20 has already been shown
 
in the skin of K5-/- mice, but not in K14-/- mice
6
. 
In our study, the levels of CCL20 were not related to the mutational status of the patients. 
To try to understand what type of inflammation was induced by the cutaneous CD4+ T cells, 
we analyzed the liquid and the roof of the blisters, and found increased levels of IL-8, IL-1β, 
IL-5 and an abundance of Th17 cytokines, at both the mRNA and protein levels. 
Unfortunately, due to the very small amount of material available and the small number of 
patients, we were not able to explore the expression of all cytokines. Increased levels of IL-1β 
and IL-8 have previously been shown in vitro and in the skin of EBS patients
7, 8, 25
. It has been 
previously shown that in the early stages of wound healing, keratinocytes become “activated” 
and release inflammatory molecules, such as IL-1 and IL-8 (to initiate innate immunity and 
subsequent neutrophil recruitment) but also CCL20 (to recruit monocytes/myeloid dendritic 
cells and T-cells into a focal skin region)
18
. Taken together, these data suggest that the 
increase in IL-1 and 8 is not specific to EBS, but is more likely to be induced by the wound 
and can partially explain the granulocytic infiltrate observed in the lesional skin. 
The increased expression of IL-5, at both mRNA level on the blister roof and at protein level 
by ELISA in the blister fluid, is an intriguing finding. IL-5 is a Th2 cytokine and a key 
mediator in eosinophil maturation, activation and recruitment. Its elevated level in skin of 
EBS patients is in accordance with the presence of eosinophils in the skin of EBS patients. 
Surprisingly, other Th2 cytokines such as IL-4 and IL-13 were not increased in our patients, 
suggesting that IgE may not play a crucial role in the development and/or progress of this 
disease. The reason for this increase is not known, however IL-5 and eosinophils are involved 
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in the physiopathology of bullous pemphigoid, an auto-immune blistering disease of the skin, 
suggesting that this data is not casual
26
. 
Here we show, for the first time, that EB is characterized by an increase in cytokines inducing 
the differentiation of T cells in Th17 cells, such as TGF-β, IL-6 and IL-21, high levels of 
Th17 effector cytokines such as IL-17, IL-21 and IL-22, and low levels of cytokines 
inhibiting the Th17 differentiation, such as IFNγ and IL-4. These data strongly suggest the 
involvement of the Th17 immune response in the pathogenesis of EBS-gen sev. Th17 cells 
play a role in adaptive immunity protecting the body against pathogens via the production of 
antimicrobial peptides, recruitment of immunocytes via induction of chemokines such as 
CCL20, and tissue repair by enhancing epithelial proliferation
27
. The Th17 signaling pathway 
is tightly controlled and is terminated after infection is ablated and tissue repair completed. 
However, the Th17 signaling is persistently activated in inflammatory or genetic diseases 
such as psoriasis
28
, rheumatoid arthritis and ichthyosis
29
. In psoriasis, Th17 cells are recruited 
by CCL20; this chemokine is released from keratinocytes by Th17 cytokines, highlighting the 
critical role of CCL20 in Th17 activation and psoriasis pathogenesis. In EBS-gen sev, 
mutation of KRT5/14 can lead to a “stressed” phenotype of keratinocytes with an uncontrolled 
Th17 activation by infection, physical or chemical stress. Based on these results, we examined 
the effect of Apremilast, an approved treatment used in psoriasis, in EBS-gen sev patients
30
. 
In the 3 treated patients, Apremilast achieved a rapid and sustained improvement. Limitations 
of this pilot therapeutic study is the limited number of patients treated and the absence of 
objective assessment of improvement; however, these patients were the most severely-
affected adult patients who had active diffuse blisters despite topical treatment. The sustained 
improvement up to 7 to 10 months of follow-up supports the value of this therapeutic 
approach. According to our results, anti-IL17 antibodies could also be of interest for treating 
EBS-gen sev patients.  
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Taken together, our results demonstrate the importance of inflammation in EBS-gen sev and 
underline the key role of Th17 activation. They also provide a promising new therapeutic 
approach for this disabling disorder. 
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Abbreviations 
EBS-gen sev: Epidermolysis bullosa simplex generalized severe  
IF: intermediate filament  
LC: Langerhans cells 
CXCL: Chemokine (C-X-C motif) ligand 
IL: interleukin  
IFNγ: interferon gamma 
TNFα: tumor necrosis factor alpha  
TGFβ: transforming growth factor beta  
CCL20: Chemokine (C-C motif) ligand 20  
 
Legends 
Table 1: Demographic and molecular features of EBS patients.  
KRT5: keratin gene, KRT14 Keratin 14 gene, NA: not available, NF: not found. AD: 
autosomal dominant, M: male, F: female, d: day, m: month, y: year. Some patients were 
included in both the retrospective and prospective study. Their number of inclusion in the 
prospective study is indicated in brackets. 
Figure 1: Immunostaining of a frozen skin biopsy of blister (patient 11) (magnification 
x100). The inflammatory infiltrate was assessed as moderate (++), dermal, perivascular and 
mainly lymphocytic, CD4+ predominant (19/22 biopsies). a) Hematoxylin-phloxine-saffron 
(HPS) stain b) total CD3+ lymphocytes, c) CD4+ T cells, d) CD8+ T cells.  
Figure 2: HPS staining of a formalin-fixed, paraffin-embedded skin biopsy (a) and blister 
roof (b and c) (x200). Epidermal and dermal infiltrate of eosinophils in the skin of patient 1 of 
the retrospective study (a). Eosinophils (b) and neutrophils (c) infiltrate the blister roof of 
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patients 2 and 6 in the prospective study, respectively. Eosinophils are indicated by blue 
arrows, neutrophils with black arrows. 
Figure 3: Quantitative PCR on the roof of an EBS-gen sev blister. 
mRNA expression of pro-inflammatory (IL-8, TNFα), Th1 (IFNγ), Th2 (IL-4, IL-5), Th17 
(IL-17, IL-21, IL-22) and regulatory (IL-10, TGFβ) cytokines. Data is presented as relative 
values with median compared to controls. The red line indicates when genes are increased 2 
or more fold.  
Figure 4: Quantitative dosage by ELISA of the blister fluid cytokines of EBS-gen sev 
patients compared to fluid of suction blisters. A- Cytokines reaching statistical difference. B- 
Th17 cells cytokines. 
Figure 5: Immunostaining for CXCL9 and CXCL10 in frozen skin biopsy (retrospective 
study) from 4 patients compared to control. CXCL9+ cells are stained green and CXCL10+ 
cells are stained red. Cells expressing both chemokines are yellow. CXCL9 was purchased 
from Life Technologies SAS (Courtaboeuf, France) and CXCL10 from Abcam (Parus, 
France), both antibodies used at 1:100 dilution.  
Figure 6: Pictures of patient 1, 2 and 3 before (a/c/e respectively) and 1.5 months after 
Apremilast treatment (b/d/f). Note the absence of blisters after treatment. 
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Table 1 
 N° Sex Age transmission Mutation 
R
et
ro
sp
e
ct
iv
e 
st
u
d
y 
1 F 3d de novo K14: c.368A>G exon 1 (p.Asn123Ser) 
2/(1) F 7 d/2y de novo K5: c.527A>G exon 1 (p.Asn176Ser) 
3 F 7 d AD NA 
4 M 7 d de novo K14 : c.416T>C exon 1 (p.Met119Thr) 
5 M 10 d de novo NA 
6 M 10 d de novo K14: c.355A>G exon 1 (p.Met119Val) 
7/(8) F 12 d / 6y de novo K5: c. XXG>A exon 7 (p.Glu466Gly)   
8  F 13 d de novo K5: c.771_772delGT exon x 
(p.Tyr258X) 
9  M 3 m de novo K14 
10 F 4 m NA K14 
11/(2) F 8 m / 2,5y de novo K5: c.556G>T, exon 2 (p.Val186leu) 
12/(3) F 4y /6y de novo K5: c.527A>G, exon 1 (p.Asn176Ser)   
13 F 8 AD NA 
14 F 22 y AD NA 
15  F 25 y AD NA 
16/(7) F 26 y/ 32y de novo K5: c. G.656-751del96pb exon 1 
(p.Val164_Lys185del) 
17 F 27 y AD K14: c.1131dupT exon 6 
P
ro
sp
ec
ti
ve
 s
tu
d
y 
4- M 43 y de novo NF 
5-  F 8 y de novo K14: c. (p.Arg125Pro) exon 1 
6- M 61 y AD K5: c.555+1G>A exon 1 
(p.Val164_Lys185 del)  
9-  M 34y AD K5: c.555+1G>A exon 1 
(p.Val164_Lys185 del)  
10- F 28y de novo K5: c.1401C>G exon 7 (p.Ile467Met) 
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Figure 3 
   
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure 4 
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